130 related articles for article (PubMed ID: 19059610)
1. GATA-3 as a marker of hormone response in breast cancer.
Fang SH; Chen Y; Weigel RJ
J Surg Res; 2009 Dec; 157(2):290-5. PubMed ID: 19059610
[TBL] [Abstract][Full Text] [Related]
2. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 expression as a predictor of hormone response in breast cancer.
Parikh P; Palazzo JP; Rose LJ; Daskalakis C; Weigel RJ
J Am Coll Surg; 2005 May; 200(5):705-10. PubMed ID: 15848360
[TBL] [Abstract][Full Text] [Related]
4. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
5. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
Badve S; Nakshatri H
J Clin Pathol; 2009 Jan; 62(1):6-12. PubMed ID: 18794199
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
Loi S
Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
[TBL] [Abstract][Full Text] [Related]
7. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
8. Luminal cells GATA have it.
Tlsty TD
Nat Cell Biol; 2007 Feb; 9(2):135-6. PubMed ID: 17268476
[No Abstract] [Full Text] [Related]
9. The significance of GATA3 expression in breast cancer: a 10-year follow-up study.
Ciocca V; Daskalakis C; Ciocca RM; Ruiz-Orrico A; Palazzo JP
Hum Pathol; 2009 Apr; 40(4):489-95. PubMed ID: 19084267
[TBL] [Abstract][Full Text] [Related]
10. [Roles of trichorhinophalangeal syndrome-1 gene in normal breast development and breast cancer].
Bao Y; Zhong ZX; Cui G; Guo L; Wang ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):121-4. PubMed ID: 23469802
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
12. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
Yamaguchi N; Ito E; Azuma S; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Tatsuta K; Inoue J; Semba K; Watanabe S
Biochem Biophys Res Commun; 2008 Jan; 365(4):711-7. PubMed ID: 18039470
[TBL] [Abstract][Full Text] [Related]
13. GATA-3 and the regulation of the mammary luminal cell fate.
Kouros-Mehr H; Kim JW; Bechis SK; Werb Z
Curr Opin Cell Biol; 2008 Apr; 20(2):164-70. PubMed ID: 18358709
[TBL] [Abstract][Full Text] [Related]
14. Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis.
Sood AK; Wang J; Mhawech-Fauceglia P; Jana B; Liang P; Geradts J
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1899-903. PubMed ID: 19505923
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
16. Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation.
Hu Y; Davies GE
Phytomedicine; 2009 Sep; 16(9):864-73. PubMed ID: 19403287
[TBL] [Abstract][Full Text] [Related]
17. [Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer].
Bershtein LM; Kovalevskiĭ AIu; Poroshina TE; Revskoĭ SIu; Kotov AV; Kovalenko IG; Tsyrlina EV; Semiglazov VF; Turkevich EA; Pozharisskiĭ KM
Vopr Onkol; 2008; 54(3):294-302. PubMed ID: 18652233
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
19. Gata-3 and mammary cell fate.
Naylor MJ; Ormandy CJ
Breast Cancer Res; 2007; 9(2):302. PubMed ID: 17381824
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
